Back

Aggregation promoting sequences rather than phosphorylation are essential for Tau-mediated toxicity in Drosophila

Cooper, A.; Richardson, B.; Ruiz Ortega, E.; Zhang, Y.; Batchelor, B.; Vaikakkara Chithran, A.; Liu, J.; Lian, T.; Ramirez Moreno, M.; Boehme, B.; Abtahi, S.; Devitt, G.; Sivanantharajah, L.; Skoulakis, E. M. C.; Allan, D. W.; Mudher, A.

2024-12-23 neuroscience
10.1101/2024.12.22.629946 bioRxiv
Show abstract

BackgroundDisease-modifying therapies for tauopathies like Alzheimers disease have targeted Tau hyperphosphorylation and aggregation, as both pathological manifestations are implicated in Tau-mediated toxicity. However, the relative contributions of these pathology-linked changes to Tau neurotoxicity remain unclear. MethodsLeveraging the genetic tractability of Drosophila, we generated multiple inducible human Tau transgenes with altered phosphorylation status and/or aggregation propensity. Their individual and combined impact was tested in vivo by quantifying Tau accumulation and neurodegenerative phenotypes in the aging fly nervous system. ResultsWe report that phospho-mimicking Tau (hTau2N4RE14) induced profound neurodegeneration, supporting a neurotoxic role for phosphorylation. However, when we rendered hTau2N4RE14 aggregation incompetent, by deleting the 306VQIVYK311 motif in the microtubule-binding region, neurotoxicity was abolished. Moreover, a peptide inhibitor targeting this motif efficaciously reduced Tau toxicity in aging Drosophila. ConclusionNeurodegeneration mediated by Tau hyperphosphorylation is gated via at least one aggregation-mediating motif on the protein. This highlights the primacy of blocking Tau aggregation in therapy, perhaps without the need to clear phosphorylated species.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Neurobiology of Disease
134 papers in training set
Top 0.3%
12.9%
2
Molecular Neurodegeneration
49 papers in training set
Top 0.1%
12.7%
3
Alzheimer's & Dementia
143 papers in training set
Top 0.9%
7.3%
4
Neurobiology of Aging
95 papers in training set
Top 0.8%
3.6%
5
Molecular Therapy
71 papers in training set
Top 0.7%
3.6%
6
Movement Disorders
62 papers in training set
Top 0.5%
3.1%
7
Acta Neuropathologica Communications
81 papers in training set
Top 0.3%
3.1%
8
GeroScience
97 papers in training set
Top 0.6%
2.9%
9
Aging Cell
144 papers in training set
Top 1%
2.8%
50% of probability mass above
10
Acta Neuropathologica
51 papers in training set
Top 0.5%
2.1%
11
PLOS ONE
4510 papers in training set
Top 48%
2.1%
12
Nature Communications
4913 papers in training set
Top 49%
1.8%
13
eneuro
389 papers in training set
Top 6%
1.7%
14
PLOS Biology
408 papers in training set
Top 11%
1.5%
15
eBioMedicine
130 papers in training set
Top 2%
1.5%
16
Cell Reports
1338 papers in training set
Top 26%
1.5%
17
Annals of Neurology
57 papers in training set
Top 1%
1.5%
18
Scientific Reports
3102 papers in training set
Top 64%
1.3%
19
Nature Aging
51 papers in training set
Top 1%
1.2%
20
Neuropathology and Applied Neurobiology
14 papers in training set
Top 0.4%
1.2%
21
Frontiers in Aging Neuroscience
67 papers in training set
Top 2%
1.2%
22
Experimental Neurology
57 papers in training set
Top 0.9%
1.2%
23
npj Aging
15 papers in training set
Top 0.7%
1.2%
24
Alzheimer's Research & Therapy
52 papers in training set
Top 2%
0.8%
25
Molecular Psychiatry
242 papers in training set
Top 3%
0.8%
26
Brain Communications
147 papers in training set
Top 3%
0.8%
27
Aging
69 papers in training set
Top 3%
0.8%
28
Journal of Alzheimer’s Disease
39 papers in training set
Top 1%
0.7%
29
Brain
154 papers in training set
Top 5%
0.7%
30
Neurology
44 papers in training set
Top 2%
0.7%